DUSP22 (Dual Specificity Phosphatase 22)

Our findings ultimately identify DUSP22 as a key inhibitor of DIC and reveal that the DUSP22-JNK axis can serve as an important therapeutic target for the treatment of DIC. This finding may offer a novel cardioprotective strategy during Dox-based cancer chemotherapy, thereby enhancing treatment safety and patient prognosis.

Notably, CLDND1 :: WRN and DUSP22 :: APOE produced the most pronounced VNC phenotypes. Together, these findings demonstrate that untargeted transcriptome-wide GF discovery, coupled with long-read isoform-level analysis and in vivo functional validation, enables the identification and prioritization of potentially novel and clinically relevant GFs that are missed by standard targeted short-read fusion panels in glioma.

Understanding the subtypes and molecular characteristics of ALCL is essential for optimizing therapeutic strategies. Therefore, this review summarizes recent research advances on ALK +/- ALCL to provide insights for optimizing treatment approaches.

P2, N=70, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Feb 2027

Our findings unveil a novel phosphorylation-dependent DUSP22-LGALS1 axis that reprograms the immunosuppressive TME. This work thus proposes a promising therapeutic strategy to overcome immune checkpoint blockade resistance in breast cancer.

We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies four molecularly distinct ALK- ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.

This is a unique presentation of LyP with concurrent DUSP22-IRF4 gene rearrangement and TCR gamma-delta phenotype along with an indolent clinical course. Diagnosing LyP can be particularly challenging due to its histologic similarities with other cutaneous lymphomas, underscoring the importance of distinguishing this relatively benign condition from more aggressive malignancies.

Histological and immunophenotypic features were consistent across skin and lymph node biopsies and supported the diagnosis of primary cutaneous origin and were managed with brentuximab vedotin-based chemotherapy, with favorable clinical responses. We emphasize the importance of thorough clinical staging and histopathological correlation to establish the correct diagnosis and the optimal treatment for cases like ours.

In patients with suspected BIA-ALCL, it is critical to properly handle the periprosthetic fluid when the disease first presents and the capsule at the time of initial capsulectomy to make a correct diagnosis and pathologic staging because a missed diagnosis may lead to disease progression. Comprehensive immunohistochemical analysis; fluorescence in situ hybridization for DUSP22, TP63, or JAK2 rearrangement; assessment of clonality of the T-cell receptor and immunoglobulin genes; and sequencing for mutations were performed as part of the workup of the submitted cases, particularly on ALK-negative ALCL cases, emphasizing the importance of ancillary testing in establishing the diagnosis.

PI3K-AKT-mTOR pathway alterations due to PIK3R1 mutations (5/28, 17.8%) were also frequent and mutually exclusive with JAK-STAT pathway activation. In summary, most T-cell neoplasms with CD30/CD15 coexpression share clinical, morphologic, immunophenotypic, and molecular features with ALK-negative ALCL but do not segregate as a homogeneous entity as defined by histologic or genetic features.

In conclusion, phosphatase DUSP22 is a novel target for preventing skeletal muscle wasting and BML-260 treatment is therapeutically effective. The DUSP22-JNK-FOXO3a axis could be exploited to treat sarcopenia or related aging disorders.